Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthélabo, dated April 26, 2004, announces a friendly improved offer to acquire Aventis, creating a new entity named Sanofi-Aventis. The transaction aims to establish the third-largest pharmaceutical group globally and the largest in Europe. The offer was unanimously approved by the Sanofi-Synthélabo Board of Directors on April 24, 2004, and recommended by the Management and Supervisory Boards of Aventis on April 25, 2004.
Key Financial Metrics and Offer Terms
The filing details the financial structure of the acquisition offer rather than standard quarterly operating results. Key metrics include:
- Offer Valuation: The improved offer values each Aventis share at €68.93 (based on average daily closing prices weighted by volume for the month ended January 21, 2004). Based on April 23, 2004 closing prices, the value is €66.63.
- Premium: The offer represents a 31.4% premium.
- Consideration Mix: The aggregate consideration is structured as 71% in shares and 29% in cash.
- Standard Entitlement: For every 6 Aventis shares tendered, shareholders receive 5 Sanofi-Synthélabo shares and €120 in cash.
- Accretion: The transaction is described as immediately accretive to adjusted net earnings from 2004 onward.
The filing text does not provide specific revenue, profit, cash flow, or debt figures for Sanofi-Synthélabo for the reporting period.
Material Changes and Strategic Shifts
The primary material change is the proposed merger with Aventis. Key strategic shifts include:
- Corporate Structure: Creation of Sanofi-Aventis with a 17-member Board of Directors (8 members from Aventis, 8 from Sanofi-Synthélabo, plus Chairman/CEO Jean-François Dehecq).
- Leadership: Jean-François Dehecq will serve as Chairman and CEO, with a management committee drawn equally from both groups.
- Legal Resolutions: Aventis will withdraw proposed resolutions regarding Plavix warrants and voting rights limitations, and all legal proceedings between the parties will be withdrawn.
Guidance, Outlook, and Risks
Outlook and Management Commentary: Management views the combination as creating value for all shareholders and achieving a strategic project to lead the European pharmaceutical market. The transaction is expected to be accretive to earnings immediately.
Conditions Precedent: The offer is conditional on shares representing more than 50% of Aventis's share capital and voting rights being tendered. Notably, the offer is not subject to the expiration of the US Hart-Scott-Rodino waiting period.
Risks and Contingencies: The filing includes a standard caution regarding forward-looking statements, noting that actual results may differ due to risks identified in the Form F-4 registration statement (File No. 333-112314). Regulatory approvals in the US, France, and Germany are required, and the transaction is subject to applicable antitrust laws.
Investor Verification Checklist
- Verify the final approval of the offer by Aventis shareholders and the successful tendering of more than 50% of Aventis shares.
- Review the Form F-4 Registration Statement (File No. 333-112314) for detailed risk factors and the full prospectus.
- Confirm the outcome of regulatory reviews in the US (Hart-Scott-Rodino), France (AMF), and Germany.
- Monitor the extraordinary meeting of Sanofi-Synthélabo shareholders scheduled for May 24, 2004, to approve the share issuance.
- Check for any amendments to the offer terms or the withdrawal of the offer if conditions are not met.